why choose us

Course: Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

CME Credits: 1.00

Released: 2021-08-11

We recently reported initial findings from a prospective cohort study which evaluated the antispike (anti-S) IgG antibody response to the SARS-CoV-2 BNT162b2 messenger RNA (mRNA) vaccine (BioNTech-Pfizer) in patients with solid tumors on active anticancer treatment vs healthy controls. After a median of approximately 5.5 weeks from the second vaccine dose, 90% of the patients with cancer (90/102) and 100% of the healthy controls (78/78) were seropositive, and the median IgG titer in the patients was significantly lower than that in the controls:1931 (interquartile range [IQR], 509-4386) AU/mL vs 7160 (IQR, 3129-11241) AU/mL; P?<?.001.


Educational Objective
To identify the key insights or developments described in this article


View Full Course